Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
mTOR & rapamycin
Video summary

SRN-901 in aging mice: 33% lifespan gain versus rapamycin, NMN and NR

The description says the compound SRN-901 extended lifespan in mice by 33% and outperformed rapamycin, NMN and NR in a head-to-head comparison. These are mouse results from one paper, not evidence of benefit for human lifespan. [1]

Automatic summary · not editorially reviewed

The key findings

  1. The description says SRN-901 extended mouse lifespan by 33%. [1]

  2. The description says SRN-901 outperformed rapamycin, NMN and NR in a head-to-head comparison. [1]

  3. The described results come from a study in aging mice, not from human data. [1]

The source at a glance

Study type / format
Video description of a mouse study (abstract-level summary)
Population / context
Aging mice in the described experiment
Summary based on
Creator description
Original publication
May 29, 2026

Mice given SRN-901 versus three anti-aging treatments

The description presents a single paper by Weiss, Skoog, Klaus and colleagues (2026) in Drug Design, Development and Therapy. It describes SRN-901 as a new compound and reports that it extended lifespan in aging mice. The comparison was head-to-head against rapamycin, NMN and NR, which the description calls the three most-hyped longevity interventions. The description does not state doses, group sizes, mouse strain or how long the animals were followed.

Supporting source [1]

Reported 33% lifespan gain and better results than all three

According to the description, SRN-901 extended mouse lifespan by 33%. It also says SRN-901 outperformed rapamycin, NMN and NR in that comparison. The description gives no separate figures for the three comparator groups and no measure of uncertainty such as variability or statistical significance. It also does not say whether healthspan, as opposed to lifespan, was measured, although the paper title mentions both.

Supporting source [1]

Mouse study described in one video; human relevance unshown

The described work is a study in aging mice, so the 33% figure and the ranking against rapamycin, NMN and NR apply to mice in that experiment. The description does not report any human data, and it does not establish that the same effects would occur in people. It also does not explain how SRN-901 works. Only the video description was available here; the video itself, the transcript and the full paper were not reviewed.

Supporting source [1]

How to interpret this

Only the video description was reviewed; the video, transcript and full paper were not. The description gives no doses, group sizes, follow-up or uncertainty measures, and no human data. Mouse findings do not show human lifespan benefits.

Based on the creator’s description; the full video and transcript were not analyzed.

Source & supporting passages

[1]
SRN-901: The Longevity Drug That Beat Rapamycin in Mice

AI x biology · youtube.com · May 29, 2026

Read the quoted passagesIn the language of the original source
  1. Finding 1 ↑

    extended mouse lifespan by 33%
  2. Finding 2 ↑

    SRN-901 outperformed all of them
  3. Finding 3 ↑

    extends lifespan and healthspan in aging mice

AI-assisted summary with linked source passages. No independent editorial or clinical review.

Our editorial method

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…